SG Americas Securities’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$399K Buy
960,000
+946,300
+6,907% +$63M ﹤0.01% 2450
2026
Q1
$8K Hold
13,700
﹤0.01% 3140
2025
Q4
$42K Hold
13,700
﹤0.01% 3385
2025
Q3
$68K Buy
+13,700
New +$1.08M ﹤0.01% 3150
2025
Q2
Sell
-62,000
Closed -$29K 3109
2025
Q1
$29K Sell
62,000
-68,000
-52% -$5.55M ﹤0.01% 3340
2024
Q4
$324K Buy
130,000
+95,000
+271% +$7.03M ﹤0.01% 1718
2024
Q3
$6K Buy
+35,000
New +$2.87M ﹤0.01% 3384
2024
Q2
Sell
-20,000
Closed -$466K 2959
2024
Q1
$466K Hold
20,000
﹤0.01% 1462
2023
Q4
$367K Hold
20,000
﹤0.01% 1671
2023
Q3
$128K Buy
+20,000
New +$2.25M ﹤0.01% 2619
2022
Q4
Sell
-65,000
Closed -$306K 3133
2022
Q3
$306K Buy
+65,000
New +$5.51M ﹤0.01% 1973

Other funds holding DXCM

SG Americas Securities's DXCM Position: Q2 2026 in Review

SG Americas Securities reduced its DexCom (DXCM) stake by 60% in Q2 2026, selling an estimated $83M and leaving 818,912 shares worth $55.2M. The position accounts for 0.03% of the portfolio, ranked #333.

SG Americas Securities first reported a position in DXCM in Q3 2013 and has held it in 43 quarters since. The position peaked at $130M in Q1 2026. 974 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • SG Americas Securities held 818,912 shares of DexCom worth $55.2M as of Q2 2026.
  • SG Americas Securities sold 1,246,365 DexCom shares in Q2 2026, an estimated $83M.
  • DexCom made up 0.03% of SG Americas Securities's portfolio in Q2 2026, its #333 holding.
  • SG Americas Securities first reported a position in DexCom in Q3 2013 and has held it in 43 quarters since.
  • SG Americas Securities's DexCom position peaked at $130M in Q1 2026.
  • 974 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.